rood blauwe elepsis logo Belegger.nl

BioPharma Terug naar discussie overzicht

Immutep De nieuwe australische Galapagos ??

582 Posts
Pagina: «« 1 2 3 4 5 6 ... 30 »» | Laatste | Omlaag ↓
  1. joostUSA 8 november 2020 16:11
    Leuk, heb hem op de watchlist gezet, vanavond even onderzoek doen. Gekocht op de ASX of de Nasdaq? Behoorlijk verschil in transactie kosten via de Giro, Ndq is behoorlijk goedkoper.
  2. Pensioen planner 8 november 2020 20:23
    ASX Announcement
    AT SOCIETY FOR IMMUNOTHERAPY OF CANCER 2020 ANNUAL MEETING
    IMMUTEP’S TACTI-002 DATA TO BE PRESENTED
    SYDNEY, AUSTRALIA – 3 November 2020 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or
    “the Company”),
    a biotechnology company developing novel immunotherapy treatments for cancer and
    autoimmune diseases, is pleased to announce more mature interim data from its phase II TACTI-002 study of eftilagimod alpha (“efti”) has been accepted as a late breaker poster presentation and poster walk for highly
    scored abstracts at the Society for Immunotherapy of Cancer (SITC
    2020 Annual Meeting,
    which is taking place as a virtual event from 9-14 November, US Eastern
    Time (US EST).
    SITC is the world’s leading member society of medical professionals dedicated to advancing cancer immunotherapy and biological therapy. Its Annual Meeting is a multidisciplinary educational and interactive
    conference focused on improving cancer patient outcomes.
    Immutep’s Poster Presentation:
    ) 35th Anniversary Standard
    Abstract title: A Phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small
    cell lung (NSCLC) or head and neck carcinoma (HNSCC)
    Abstract #: 790
    Date & time: Presenter:
    Monday 9 November 2020, 8am US EST
    Dr Matthew Krebs, The Christie NHS Foundation Trust, Manchester, UK
    Immutep will make the poster presentation available on its website following its publication at SITC 2020.
    About TACTI-002
    TACTI-002 is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada). It is evaluating the combination of efti with MSD’s KEYTRUDA® (or
    pembrolizumab, an anti-PD-1 therapy) in up to 109 patients.
    About Immutep
    Immutep is a globally active biotechnology company that is a leader in the development of LAG-3
    immunotherapies for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM) and the NASDAQ
    (IMMP) in the United States.
    Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3Ig fusion protein which is a first-in-class antigen presenting cell (APC) activator and is being explored in cancer and infectious disease.
    Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000 ABN: 90 009 237 889

    Additional LAG-3 products, including antibodies, for immune response modulation in autoimmunity and cancer are being developed by Immutep’s large pharmaceutical partners. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.
    Further information can be found on the Company’s website www.immutep.com or by contacting:
    Australian Investors/Media:
    Catherine Strong, Citadel-MAGNUS
    +61 (0)406 759 268; cstrong@citadelmagnus.com
    U.S. Media:
    Tim McCarthy, LifeSci Advisors
    +1 (212) 915.2564; tim@lifesciadvisors.com
    This announcement was authorised for release by the Chief Executive Officer of Immutep Limited.
    Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000 ABN: 90 009 237 889
  3. Pensioen planner 8 november 2020 20:24
    quote:

    joostUSA schreef op 8 november 2020 16:11:

    Leuk, heb hem op de watchlist gezet, vanavond even onderzoek doen. Gekocht op de ASX of de Nasdaq? Behoorlijk verschil in transactie kosten via de Giro, Ndq is behoorlijk goedkoper.
    Ik heb ze op ASX gekocht.
    Maar volgens mij maakt het niet veel uit..

    Groet,
    PP
  4. Maisha marefu 8 november 2020 22:54
    quote:

    Pensioen planner schreef op 8 november 2020 20:24:

    [...]

    Ik heb ze op ASX gekocht.
    Maar volgens mij maakt het niet veel uit..

    Groet,
    PP
    Maakt inderdaad niets uit.
  5. RW1963 10 november 2020 19:00
    quote:

    Thijs020 schreef op 10 november 2020 16:54:

    Toch wel een flinke terugval nu..
    Helaas wel, terwijl ik er gisteren net een plukje heb bijgekocht. Nou ja, wij moeten er het beste maar van hopen.
    Vandaag procentueel mijn grootste daler :-(
  6. Maisha marefu 11 november 2020 19:54
    Ziet er voorlopig goed uit.

    Ze hebben ook een patent genomen en dat doen ze niet voor niets mijn gedacht.

    Zie bovenstaande 2 verschillende links.
  7. Moneycollector 12 november 2020 15:20
    Zeker interessant aandeel. Mooie pijplijn. Weet iemand iets van de cash positie van dit bedrijf?
    Als ik zelf weer cash heb gaat het hier misschien wel naar toe!
582 Posts
Pagina: «« 1 2 3 4 5 6 ... 30 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 6.997
AB InBev 2 5.479
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.114
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.445
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.622
Aedifica 3 900
Aegon 3.258 322.599
AFC Ajax 537 7.084
Affimed NV 2 6.287
ageas 5.844 109.883
Agfa-Gevaert 14 2.046
Ahold 3.538 74.287
Air France - KLM 1.025 34.972
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.017
Alfen 16 24.222
Allfunds Group 4 1.467
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 403
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.485 114.806
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.834 242.585
AMG 971 132.996
AMS 3 73
Amsterdam Commodities 305 6.685
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 481
Antonov 22.632 153.605
Aperam 92 14.885
Apollo Alternative Assets 1 17
Apple 5 375
Arcadis 252 8.731
Arcelor Mittal 2.033 320.441
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.281
Aroundtown SA 1 219
Arrowhead Research 5 9.715
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.060
ASML 1.766 105.281
ASR Nederland 21 4.450
ATAI Life Sciences 1 7
Atenor Group 1 465
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.579
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.383